

D2
5. (Three times amended) The polypeptide of claim 1, wherein a glutamic acid or a phenylalanine residue is substituted at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

Sub
P1
7. (Four times amended) The polypeptide of claim 1, wherein said modified GLA domain further comprises an amino acid substitution at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

8. (Twice amended) The polypeptide of claim 7, wherein a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

9. (Twice amended) The polypeptide of claim 3, wherein said modified GLA domain further comprises a substitution of a glutamic acid or an aspartic acid at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

D3
10. (Three times amended) The polypeptide of claim 5, wherein said modified GLA domain further comprises a substitution of a glutamic acid or an aspartic acid at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

11. (Twice amended) The polypeptide of claim 3, wherein said modified GLA domain further comprises a substitution of a glutamic acid or a phenylalanine at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

12. (Twice amended) The polypeptide of claim 11, wherein said modified GLA domain comprises a glutamic acid or an aspartic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4.

13. (Twice amended) The polypeptide of claim 9, wherein said modified GLA domain comprises a glutamine residue at amino acid 10 and a glutamic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4.

D3 14. (Twice amended) The polypeptide of claim 11, wherein said modified GLA domain comprises a substitution of a glutamine at residue 10 and a phenylalanine at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

Sub D4 17. (Three times amended) A Factor VII or Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native Factor VII or Factor VIIa polypeptide, said modified GLA domain comprising an aspartic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4. --

Please add new claims 23-27:

glb 23. (New) A Factor VII or Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native Factor VII or Factor VIIa polypeptide, said modified GLA domain consisting essentially of amino acid substitutions at two or more of the residues selected from the group consisting of residues 10, 11, 28, and 32 of SEQ ID NO:3 or SEQ ID NO:4.

D3 24. (New) The polypeptide of claim 23, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

25. (New) The polypeptide of claim 23, wherein a glutamine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

26. (New) The polypeptide of claim 23, wherein a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

27. (New) The polypeptide of claim 23, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4 and a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4. --